

## SEQUENCE LISTING

<110> Japan Science and Technology Corporation, and  
Director-General, National Institute of Infectious Diseases

<120> A recombinant BCG vaccine

<130> 02-F-049PCT

<140>

<141>

<150> JP2002-237610

<151> 2002-08-16

<160> 5

<210> 1

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of artificial Sequence: Synthetic oligonucleotide

<400> 1

aatggatcct atagtgcaga acctc

25

<210> 2

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of artificial Sequence: Synthetic oligonucleotide

<400> 2

aatgggccct tacaaaactc ttgctttatg g

31

<210> 3

<211> 706

<212> DNA

## &lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (5).. (700)

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Synthetic polynucleotide

&lt;400&gt; 3

ggat ccg atc gtc cag aac ctg cag ggc cag atg gtc cac cag gcc atc	49
Pro Ile Val Gln Asn Leu Gln Gly Gln Met Val His Gln Ala Ile	
1 5 10 15	
tcg ccg cgc acc ctg aac gcc tgg gtc aag gtc gtc gag gag aag gcc	97
Ser Pro Arg Thr Leu Asn Ala Trp Val Lys Val Val Glu Glu Lys Ala	
20 25 30	
ttc tcg ccg gag gtc atc ccg atg ttc tcg gcc ctg tcg gag ggc gcc	145
Phe Ser Pro Glu Val Ile Pro Met Phe Ser Ala Leu Ser Glu Gly Ala	
35 40 45	
acc ccg cag gac ctg aac acc atg ctg aac acc gtc ggc ggc cac cag	193
Thr Pro Gln Asp Leu Asn Thr Met Leu Asn Thr Val Gly Gly His Gln	
50 55 60	
gcc gcc atg cag atg ctg aag gag acc atc aac gag gag gcc gcc gag	241
Ala Ala Met Gln Met Leu Lys Glu Thr Ile Asn Glu Glu Ala Ala Glu	
65 70 75	
tgg gac cgc ctg cac ccg gtc cac gcc ggc ccc atc gca ccg ggc cag	289
Trp Asp Arg Leu His Pro Val His Ala Gly Pro Ile Ala Pro Gly Gln	
80 85 90 95	
atg cgc gag cct cgc ggc tcg gac atc gcc ggc acc acc tcg acc ctc	337
Met Arg Glu Pro Arg Gly Ser Asp Ile Ala Gly Thr Thr Ser Thr Leu	
100 105 110	
cag gag cag atc ggc tgg atg acc cac aac ccg ccg atc ccg gtc ggc	385
Gln Glu Gln Ile Gly Trp Met Thr His Asn Pro Pro Ile Pro Val Gly	
115 120 125	
gag atc tac aag cgc tgg atc atc ctg ggc ctg aac aag atc gtc cgc	433

Glu Ile Tyr Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys Ile Val Arg  
 130 135 140

atg tac tcg ccg acc tcg atc ctg gac atc cgc cag ggt ccg aag gag 481  
 Met Tyr Ser Pro Thr Ser Ile Leu Asp Ile Arg Gln Gly Pro Lys Glu  
 145 150 155

ccg ttc cgc gac tac gtc gac cgc ttc tac aag acc ctc cgc gcc gag 529  
 Pro Phe Arg Asp Tyr Val Asp Arg Phe Tyr Lys Thr Leu Arg Ala Glu  
 160 165 170 175

cag gcg tcg cag gag gtc aag aac tgg atg acc gag acc ctg ctg gtc 577  
 Gln Ala Ser Gln Glu Val Lys Asn Trp Met Thr Glu Thr Leu Leu Val  
 180 185 190

cag aac gcc aac ccg gac tgc aag acc atc ctg aag gcc ctg ggt ccg 625  
 Gln Asn Ala Asn Pro Asp Cys Lys Thr Ile Leu Lys Ala Leu Gly Pro  
 195 200 205

ggc gcc acc ctg gag gag atg atg acc gcc tgc cag ggc gtc ggc ggc 673  
 Gly Ala Thr Leu Glu Glu Met Met Thr Ala Cys Gln Gly Val Gly Gly  
 210 215 220

ccg ggc cac aag gcg cgc gtc ctg taa gggccc 706  
 Pro Gly His Lys Ala Arg Val Leu  
 225 230

<210> 4

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of artificial Sequence: Synthetic oligopeptide

<400> 4

Leu Glu Arg Phe Ala Val Asn Pro Gly Leu Leu Glu Thr Ser Glu  
 1 5 10 15

<210> 5

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of artificial Sequence: Synthetic oligopeptide

<400> 5

Asn	Ile	Gln	Gly	Gln	Met	Val	His	Gln	Ala	Ile	Ser	Pro	Arg	Thr
1				5				10					15	